Compare OSPN & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSPN | ZURA |
|---|---|---|
| Founded | 1991 | 2022 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 390.0M | 521.8M |
| IPO Year | 2000 | N/A |
| Metric | OSPN | ZURA |
|---|---|---|
| Price | $10.93 | $5.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $16.67 | $13.00 |
| AVG Volume (30 Days) | 532.8K | ★ 593.9K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.75% | N/A |
| EPS Growth | ★ 28.77 | N/A |
| EPS | ★ 1.88 | N/A |
| Revenue | ★ $243,180,000.00 | N/A |
| Revenue This Year | $3.22 | N/A |
| Revenue Next Year | $3.16 | N/A |
| P/E Ratio | $5.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.07 | $0.99 |
| 52 Week High | $18.13 | $7.25 |
| Indicator | OSPN | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 53.09 | 45.02 |
| Support Level | $10.20 | $5.35 |
| Resistance Level | $10.98 | $5.75 |
| Average True Range (ATR) | 0.38 | 0.39 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 64.02 | 40.57 |
OneSpan Inc is a provider of information technology security solutions for banking and financial services and application security markets. The company build secure, seamless, and trusted digital experiences through two solution portfolios: Cybersecurity solutions engaged in protecting identities, securing mobile apps, and safeguarding access through high-assurance authentication, threat intelligence, fraud prevention, and robust mobile app protection, defending users, devices, and applications against sophisticated attacks, while Digital agreement solutions focuses on streamlining workflows with secure e-signatures, identity verification, and smart digital forms, built to enable speed, compliance and other customer experiences.
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.